Sepia ink oligopeptide induces apoptosis in prostate cancer cell lines via caspase-3 activation and elevation of Bax/Bcl-2 ratio

Marine Drugs

Volumn 10, Issue 10, 2012, Pages 2153-2165

  Huang, Fangfang ^a   Yang, Zuisu ^a   Yu, Di ^a   Wang, Jiabin ^b   Li, Rong ^a   Ding, Guofang ^a  

^a ZHEJIANG OCEAN UNIVERSITY   (China)

^b Zhijiang Hailisheng Group Co Ltd   (China)

Author keywords

Apoptosis; Oligopeptide; Proliferation; Prostate cancer

Indexed keywords

EID: 84868258164     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md10102153     Document Type: Article

References (26)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Baade, P.D.; Youlden, D.R.; Krnjacki, L.J. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol. Nutr. Food Res. 2009, 53, 171-184.
3. Bray, F.; Lortet-Tieulent, J.; Ferlay, J.; Forman, D.; Auvinen, A. Prostate cancer incidence and mortality t rends in 37 European countries: An overview. Eur. J. Cancer 2010, 46, 3040-3052.
4. Kvale, R.; Moller, B.; Angelsen, A.; Dahl, O.; Fosså, S.D.; Halvorsen, O.J.; Hoem, L.; Solberg, A.; Wahlqvist, R.; Bray, F. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Cancer Epidemiol. 2010, 34, 359-367.
5. Hong, H.; Zhang, Y.; Sun, J.; Cai, W. Positron emission tomography imaging of prostate cancer. Amino Acids 2009, 39, 11-27.
6. Braun, K.; Ehemann, V.; Wiessler, M.; Pipkorn, R.; Didinger, B.; Mueller, G.; Waldeck, W. High-resolution flow cytometry: A suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment. Int. J. Med. Sci. 2009, 6, 338-347.
7. Peyromaure, M.; Valéri, A.; Rebillard, X.; Beuzeboc, P.; Soulié, M.; Salomon, L. Characteristics of prostate cancer in men less than 50-year-old. Prog. Urol. 2009, 19, 803-809.
8. Boiardi, A.; Silvan, A.; Milanesi, I.; Botturi, M.; Broggi, G. Primary glial tumor patients treated by combining cis-platin and etoposide. J. Neurooncol. 1991, 11, 165-170.
9. Jeremic, B.; Grujicic, D.; Jevremovic, S.; Stanisavljevic, B.; Milojevic, L.; Djuric, L.; Mijatovic, L. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J. Clin. Oncol. 1992, 10, 1074-1077.
10. White, L.; Sterling-Levis, K.; Fisher, R.; Tobias, V. Response of brain tumors to chemotherapy, evaluated in a clinically relevant xenograft model. J. Neurooncol. 1995, 25, 39-47.
11. Goel, S.; Mita, A.C.; Mita, M.; Rowinsky, E.K.; Chu, Q.S.; Wong, N.; Desjardins, C.; Fang, F.; Jansen, M.; Shuster, D.E.; et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin. Cancer Res. 2009, 15, 4207-4212.
12. Hadaschik, B.A.; Adomat, H.; Fazli, L.; Fradet, Y.; Andersen, R.J.; Gleave, M.E.; So, A.I. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, A Synthetic analogue of the marine sponge product hemiasterlin. Clin. Cancer Res. 2008, 14, 1510-1518.
13. Den Brok, M.W.; Nuijen, B.; Meijer, D.M.; Millán, E.; Manada, C.; Beijnen, J.H. Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. PDA J. Pharm. Sci. Technol. 2005, 59, 246-257.
14. Luesch, H.; Moore, R.E.; Paul, V.J.; Mooberry, S.L.; Corbett, T.H. Isolation of dolastatin 10 analogue from the marine cyanobacterium symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 2001, 64, 907-910.
15. Hoffman, M.A.; Blessing, J.A.; Lentz, S.S.; Gynecologic Oncology Group Study. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol. Oncol. 2003, 89, 95-98.
16. Simmons, T.L.; Andrianasolo, E.; McPhail, K.; Flatt, P.; Gerwick, W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther. 2005, 4, 333-342.
17. Naraoka, T.; Chung, H.S.; Uchisawa, H.; Sasaki, J.; Matsue, H. Tyrosinase activity in antitumor compounds of squid ink. Food Sci. Technol. Res. 2000, 6, 171-175.
18. Zeng, M.J.; Zhang, D.M.; Chen, J.H. Research advances of antitumor peptides. Chin. J. Biochem. Pharm. 2007, 28, 139-141.
19. Ding, G.F.; Huang, F.F.; Yang, Z.S.; Yu, D.; Yang, Y.F. Anticancer activity of an oligopeptide isolated from hydrolysates of Sepia ink. Chin. J. Nat. Med. 2011, 9, 151-155.
20. Martin, S.J.; Green, D.R. Apoptosis and cancer: The failure of controls on cell death and cell survival. Crit. Rev. Oncol. Hematol. 1995, 8, 137-153.
21. Pan, G.; O'Rourke, K.; Chinnaiyan, A.M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276, 111-113.
22. Zapata, J.M.; Pawlowski, K.; Haas, E.; Ware, C.F.; Godzik, A.; Reed, J.C. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J. Biol. Chem. 2001, 276, 24242-24252.
23. Ashe, P.C.; Berry, M.D. Apoptotic signaling cascades. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27, 199-214.
24. Cory, S.; Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2, 647-656.
25. Ghobrial, I.M.; Witzig, T.E.; Adjei, A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55, 178-194.
26. Mirjolet, J.F.; Barberi-Heyob, M.; Didelot, C.; Peyrat, J.P.; Abecassis, J.; Millon, R.; Merlin, J.L. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br. J. Cancer 2000, 83, 1380-1386.